Our Pricing

Understanding Wegovy 2.4mg Equivalent to Mounjaro Dosing

Published: 10 September 2026

When comparing wegovy 2.4 equivalent to mounjaro, patients often ask which tirzepatide dose matches semaglutide's maximum 2.4mg strength for weight loss. While both medications are GLP-1 receptor agonists licensed by the MHRA for chronic weight management, they work through different mechanisms and cannot be directly converted dose-for-dose. Our UK clinical team explains the pharmacological differences, comparative efficacy data, and how these treatments compare in real-world practice.

Wegovy 2.4 Equivalent to Mounjaro: Mechanism Differences

Understanding wegovy 2.4 equivalent to mounjaro requires recognising that semaglutide and tirzepatide are fundamentally different molecules. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist [1]. This dual mechanism means tirzepatide activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, potentially offering enhanced metabolic effects.

Because of these mechanistic differences, there is no direct milligram-to-milligram equivalency between wegovy 2.4 equivalent to mounjaro doses. The MHRA has licensed Wegovy at a maximum maintenance dose of 2.4mg weekly, whilst Mounjaro's maintenance doses range from 5mg to 15mg weekly [2]. Clinical trials used different endpoints and populations, making direct dose comparisons scientifically imprecise. However, comparative efficacy data from the SURPASS and STEP programmes can help UK prescribers determine which treatment may suit individual patients.

Clinical Trial Data: Wegovy 2.4 Equivalent to Mounjaro Efficacy

When evaluating wegovy 2.4 equivalent to mounjaro in terms of weight loss outcomes, the STEP 1 trial showed semaglutide 2.4mg achieved an average 14.9% body weight reduction over 68 weeks in adults with obesity [1]. In contrast, the SURMOUNT-1 trial demonstrated tirzepatide 15mg resulted in an average 20.9% weight reduction, whilst the 10mg dose achieved 19.5%, and 5mg achieved 15.0% over 72 weeks [3].

These data suggest that wegovy 2.4 equivalent to mounjaro may align most closely with Mounjaro 5mg in terms of percentage weight loss, though individual responses vary considerably. The higher Mounjaro doses of 10mg and 15mg appear to exceed Wegovy 2.4mg's efficacy in head-to-head trial comparisons. UK prescribers typically consider patient tolerance, medical history, and cost when selecting between these options, as both require ongoing clinical assessment and lifestyle modifications.

SURPASS vs STEP Trials: What the Evidence Shows

The SURPASS programme evaluated tirzepatide across multiple doses, whilst the STEP trials assessed semaglutide. When comparing wegovy 2.4 equivalent to mounjaro using these datasets, we observe that tirzepatide's dual agonist activity may confer additional metabolic benefits beyond GLP-1 stimulation alone [3]. Both medications demonstrated significant improvements in glycaemic control, blood pressure, and lipid profiles in addition to weight reduction, though tirzepatide showed numerically greater HbA1c reductions in diabetic populations.

Dosing Schedules: Wegovy 2.4 Equivalent to Mounjaro Titration

Both medications require gradual dose escalation to minimise gastrointestinal side effects. For wegovy 2.4 equivalent to mounjaro comparisons, Wegovy's titration schedule starts at 0.25mg weekly, increasing monthly to reach 2.4mg by week 17 [2]. Mounjaro begins at 2.5mg weekly, escalating every four weeks to reach maintenance doses of 5mg, 10mg, or 15mg depending on individual tolerance and efficacy.

UK prescribers determine the optimal maintenance dose based on weight loss response and tolerability. When considering wegovy 2.4 equivalent to mounjaro, patients who experience adequate weight loss and good tolerance on Mounjaro 5mg may not require escalation to higher doses. Conversely, those on Wegovy 2.4mg who plateau or seek additional weight reduction cannot increase the semaglutide dose further, as 2.4mg is the licensed maximum for weight management.

Side Effect Profiles: Wegovy 2.4 Equivalent to Mounjaro Tolerability

Both semaglutide and tirzepatide share similar gastrointestinal side effects, including nausea, vomiting, diarrhoea, and constipation [1][3]. When comparing wegovy 2.4 equivalent to mounjaro for tolerability, clinical trial data suggest that higher doses of both medications increase the incidence of GI adverse events. Mounjaro's dual agonist mechanism may produce slightly different side effect patterns, though real-world tolerability varies widely between individuals.

UK clinical experience shows that gradual titration, taking the injection with food timing adjustments, and staying well-hydrated can mitigate many side effects. For wegovy 2.4 equivalent to mounjaro decisions, patients who cannot tolerate Wegovy 2.4mg may not necessarily tolerate Mounjaro 5mg or higher doses, as individual sensitivity differs. Both medications require ongoing monitoring by UK prescribers, with dose adjustments or treatment discontinuation if side effects become unmanageable.

Managing Gastrointestinal Effects Across Both Treatments

Our UK clinical team advises patients starting either medication to eat smaller, more frequent meals and avoid high-fat foods during the initial titration period. When considering wegovy 2.4 equivalent to mounjaro, the side effect management strategies remain consistent across both treatments, as the GLP-1 component drives most gastrointestinal symptoms through delayed gastric emptying [2].

Cost Considerations: Wegovy 2.4 Equivalent to Mounjaro UK Pricing

At Cured Pharmacy, Wegovy is available from £124.99, whilst Mounjaro starts from £124.99, reflecting the different manufacturing costs and market positioning of these newer weight loss medications. When evaluating wegovy 2.4 equivalent to mounjaro from a cost perspective, patients should consider the total treatment duration and individual response rates rather than solely comparing per-dose pricing.

UK patients can access £20 off their first order with code Weightlossnew, making these evidence-based treatments more accessible. For wegovy 2.4 equivalent to mounjaro cost comparisons, it's essential to factor in the clinical assessment fee, ongoing monitoring requirements, and potential need for dose adjustments. Both medications require prescription approval from a UK-registered prescriber following a comprehensive online consultation assessing medical history, contraindications, and suitability.

Choosing Between Treatments: Wegovy 2.4 Equivalent to Mounjaro Guidance

UK prescribers consider multiple factors when recommending between these medications, including BMI, comorbidities, previous weight loss attempts, and patient preferences. When discussing wegovy 2.4 equivalent to mounjaro with patients, our clinical team at Cured Pharmacy reviews individual medical histories, current medications, and weight loss goals to determine the most appropriate option.

For patients who have tried Wegovy 2.4mg and seek additional efficacy, Mounjaro's higher doses may offer enhanced weight reduction, though this requires careful clinical assessment and cannot be guaranteed. Conversely, those new to GLP-1 medications may prefer starting with Wegovy's established safety profile and lower cost. Understanding wegovy 2.4 equivalent to mounjaro helps patients make informed decisions alongside their UK prescriber, ensuring treatment aligns with individual clinical needs and expectations.

Personalised Treatment Selection at Cured Pharmacy

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and UK clinical team provide individualised guidance on wegovy 2.4 equivalent to mounjaro comparisons during the online consultation process. We assess your complete medical profile, discuss realistic weight loss expectations, and ensure you receive the most clinically appropriate treatment with transparent upfront pricing and discreet UK delivery [4].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 10 September 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 10 September 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
4. General Pharmaceutical Council. (2024). Registered Pharmacies and Pharmacists. GPhC Register. [accessed 10 September 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.